Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.

PubWeight™: 1.25‹?› | Rank: Top 10%

🔗 View Article (PMC 3583506)

Published in J Pharmacol Exp Ther on December 17, 2012

Authors

Rajendar K Mittapalli1, Shruthi Vaidhyanathan, Arkadiusz Z Dudek, William F Elmquist

Author Affiliations

1: Department of Pharmaceutics, Brain-Barriers Research Center, University of Minnesota, Minneapolis, MN, USA.

Associated clinical trials:

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 | NCT01072175

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain (Break MB) | NCT01266967

Articles citing this

Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol (2015) 0.98

A case of intracranial hemorrhage caused by combined dabrafenib and trametinib therapy for metastatic melanoma. Am J Case Rep (2014) 0.96

Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases. Drug Metab Dispos (2014) 0.92

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol (2016) 0.87

Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases. Pigment Cell Melanoma Res (2015) 0.86

Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system. J Pharmacol Exp Ther (2013) 0.86

New strategies in pediatric gliomas: molecular advances in pediatric low-grade gliomas as a model. Clin Cancer Res (2013) 0.84

Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res (2016) 0.81

A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. Oncologist (2015) 0.79

The BRAF kinase domain promotes the development of gliomas in vivo. Genes Cancer (2015) 0.79

The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy. Acta Pharm Sin B (2014) 0.79

In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways. Int J Mol Sci (2014) 0.78

Targeted Therapies for Melanoma Brain Metastases. Curr Treat Options Neurol (2017) 0.77

Current treatment options of brain metastases and outcomes in patients with malignant melanoma. Rep Pract Oncol Radiother (2015) 0.77

Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model. Oncotarget (2016) 0.77

Caloric restriction coupled with radiation decreases metastatic burden in triple negative breast cancer. Cell Cycle (2016) 0.77

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. Mol Cancer Ther (2015) 0.77

Challenges in the delivery of therapies to melanoma brain metastases. Curr Pharmacol Rep (2016) 0.75

Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. J Pharmacol Exp Ther (2015) 0.75

Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro Oncol (2017) 0.75

Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy. Int J Cancer (2016) 0.75

Unmasking the Role of Uptake Transporters for Digoxin Uptake Across the Barriers of the Central Nervous System in Rat. J Cent Nerv Syst Dis (2017) 0.75

Melanoma Brain Metastasis: Mechanisms, Models, and Medicine. Int J Mol Sci (2016) 0.75

Renal Drug Transporters and Drug Interactions. Clin Pharmacokinet (2017) 0.75

Drug Delivery to Melanoma Brain Metastases: Can Current Challenges Lead to New Opportunities? Pharmacol Res (2017) 0.75

Articles cited by this

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin (2011) 30.81

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86

Management of cutaneous melanoma. N Engl J Med (2004) 9.52

The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev (2005) 7.56

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71

Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev (2003) 3.69

Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res (2010) 3.35

The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res (2007) 3.04

Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89

DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat Rep (1976) 2.59

Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol (2004) 2.36

Prognostic factors for survival in melanoma patients with brain metastases. Cancer (2010) 2.23

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther (2003) 1.93

Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm (1988) 1.89

An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos (2008) 1.86

P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res (2007) 1.74

The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther (2010) 1.59

Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther (2010) 1.57

Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol (1996) 1.48

Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos (2007) 1.44

Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin Cancer Res (2009) 1.42

Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther (2012) 1.26

Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Curr Opin Investig Drugs (2008) 1.25

Applying Bailer's method for AUC confidence intervals to sparse sampling. Pharm Res (1995) 1.19

Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design. Drug Metab Dispos (2008) 1.00

Melanoma brain metastases and vemurafenib: need for further investigation. Mayo Clin Proc (2012) 1.00

Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Mol Pharm (2012) 0.95

Extending the reach of BRAF-targeted cancer therapy. Lancet (2012) 0.80

Articles by these authors

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol (2012) 2.52

Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol (2007) 2.19

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther (2003) 1.93

Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol (2010) 1.84

The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther (2010) 1.59

Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther (2010) 1.57

P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J Pharmacol Exp Ther (2009) 1.56

Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr Pharm Des (2011) 1.47

Novel insulin-like growth factor-methotrexate covalent conjugate inhibits tumor growth in vivo at lower dosage than methotrexate alone. Transl Res (2009) 1.42

Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med (2011) 1.42

Drug efflux transporters in the CNS. Adv Drug Deliv Rev (2003) 1.37

AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res (2007) 1.35

Collision tumor versus multiphenotypic differentiation: a case of carcinoma with features of colonic and lung primary tumors. Anticancer Res (2009) 1.35

Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther (2012) 1.26

Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg (2009) 1.19

Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos (2012) 1.19

Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung. Clin Lung Cancer (2010) 1.19

Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85. Pharm Res (2003) 1.17

Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice. Drug Metab Dispos (2012) 1.13

Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol (2010) 1.12

CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. Pigment Cell Melanoma Res (2011) 1.09

Distribution kinetics of a micelle-forming block copolymer Pluronic P85. J Control Release (2004) 1.09

Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J Biol Chem (2004) 1.06

P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution. Drug Metab Dispos (2007) 1.06

Rare case of hemangiopericytoma responds to sunitinib. Transl Res (2008) 1.05

Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases. Anticancer Res (2009) 1.03

Profound impairment of adaptive immune responses by alkylating chemotherapy. J Immunol (2013) 1.02

AAPS-FDA Workshop White Paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol (2007) 1.01

Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design. Drug Metab Dispos (2008) 1.00

Inhibition of mesothelin as a novel strategy for targeting cancer cells. PLoS One (2012) 1.00

Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol (2011) 0.99

Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm Res (2005) 0.99

A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma. Clin Cancer Res (2009) 0.97

Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. Drug Metab Dispos (2007) 0.97

Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis. J Cereb Blood Flow Metab (2006) 0.97

Diminished neo-antigen response to keyhole limpet hemocyanin (KLH) vaccines in patients after treatment with chemotherapy or hematopoietic cell transplantation. Clin Immunol (2005) 0.97

Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse. Drug Metab Dispos (2008) 0.96

Distribution of the novel antifolate pemetrexed to the brain. J Pharmacol Exp Ther (2005) 0.95

Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin. J Neuroophthalmol (2008) 0.94

Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents. Mol Cancer Ther (2012) 0.94

Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells. J Pharmacol Exp Ther (2004) 0.94

Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium. Neuro Oncol (2004) 0.92

Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone. Eur J Cancer (2008) 0.91

Determination of cediranib in mouse plasma and brain tissue using high-performance liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 0.90

A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. Am J Clin Oncol (2012) 0.90

Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines. J Bone Joint Surg Am (2010) 0.90

Brain distribution of cediranib is limited by active efflux at the blood-brain barrier. J Pharmacol Exp Ther (2012) 0.89

Pulmonary blastoma with renal metastasis responds to sorafenib. J Thorac Oncol (2007) 0.89

Brain distribution and bioavailability of elacridar after different routes of administration in the mouse. Drug Metab Dispos (2012) 0.89

Development of a respirable, sustained release microcarrier for 5-fluorouracil I: In vitro assessment of liposomes, microspheres, and lipid coated nanoparticles. J Pharm Sci (2006) 0.89

Ral overactivation in malignant peripheral nerve sheath tumors. Mol Cell Biol (2009) 0.88

Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain. J Pharmacol Exp Ther (2013) 0.88

Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era. Anticancer Res (2014) 0.88

Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors. J Pharm Sci (2008) 0.88

Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance. Mol Pharm (2012) 0.88

pH-Dependent transport of pemetrexed by breast cancer resistance protein. Drug Metab Dispos (2011) 0.87

A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines. Invest New Drugs (2007) 0.87

Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system. J Pharmacol Exp Ther (2013) 0.86

Enzastaurin renders MCF-7 breast cancer cells sensitive to radiation through reversal of radiation-induced activation of protein kinase C. Eur J Cancer (2008) 0.85

OCT2 and MATE1 provide bidirectional agmatine transport. Mol Pharm (2010) 0.85

Polymorphisms in DNA repair gene XRCC1 and skin cancer risk: a meta-analysis. Anticancer Res (2011) 0.85

Mitoxantrone permeability in MDCKII cells is influenced by active influx transport. Mol Pharm (2007) 0.85

Large-cell neuroendocrine carcinoma of the cervix. Rare Tumors (2012) 0.85

Utilizing transmembrane convection to enhance solute sampling and delivery by microdialysis: theory and in vitro validation. J Memb Sci (2010) 0.84

Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability. J Pharm Sci (2013) 0.84

Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. J Thorac Oncol (2010) 0.84

Measurement of drug release from microcarriers by microdialysis. J Pharm Sci (2005) 0.84

Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate. Drug Metab Dispos (2013) 0.84

Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancer. Clin Lung Cancer (2013) 0.84

Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case report. J Thorac Oncol (2008) 0.83

Vaccine therapy for metastatic melanoma: systematic review and meta-analysis of clinical trials. Melanoma Res (2011) 0.83

Metanephric adenoma of the kidney: an unusual diagnostic challenge. Rare Tumors (2010) 0.82

Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy. Anticancer Res (2012) 0.82

Primary hepatic leiomyosarcoma in adults: analysis of prognostic factors. Onkologie (2012) 0.82

Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors. Clin Genitourin Cancer (2012) 0.81

Treatment of melanoma-associated retinopathy. Curr Treat Options Neurol (2010) 0.81

Novel Ras pathway inhibitor induces apoptosis and growth inhibition of K-ras-mutated cancer cells in vitro and in vivo. Transl Res (2008) 0.80

A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer. Lung Cancer (2012) 0.80

Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors. Am J Clin Oncol (2016) 0.80

Capecitabine for skin cancer prevention in solid organ transplant recipients. Clin Transplant (2010) 0.79

Review of selected patents for cancer therapy targeting tumor angiogenesis. Recent Pat Anticancer Drug Discov (2006) 0.79

A 3-D model of tumor progression based on complex automata driven by particle dynamics. J Mol Model (2009) 0.79

Organic cation uptake is enhanced in bcrp1-transfected MDCKII cells. Mol Pharm (2010) 0.79

Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors. Pharmacogenomics (2012) 0.79

SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis. Transl Res (2007) 0.79

Sorafenib induces partial response in metastatic medullary thyroid carcinoma. Acta Oncol (2010) 0.79

Development of a respirable, sustained release microcarrier for 5-fluorouracil II: In vitro and in vivo optimization of lipid coated nanoparticles. J Pharm Sci (2006) 0.79

Skin ulcers in Klippel-Trenaunay syndrome respond to sunitinib. Transl Res (2008) 0.79

Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. Invest New Drugs (2013) 0.78

Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review. Cancer Invest (2010) 0.78

Randomized phase II study of IL-2 with or without an allogeneic large multivalent immunogen vaccine for the treatment of stage IV melanoma. Am J Clin Oncol (2014) 0.78

Local irradiation in combination with bevacizumab enhances radiation control of bone destruction and cancer-induced pain in a model of bone metastases. Int J Cancer (2008) 0.78

MT103 inhibits tumor growth with minimal toxicity in murine model of lung carcinoma via induction of apoptosis. Invest New Drugs (2010) 0.78

Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens. Breast Cancer Res Treat (2006) 0.77

Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors. Am J Clin Oncol (2011) 0.77

MARCKS is marked in combating lung cancer growth and acquired resistance. Am J Respir Crit Care Med (2014) 0.77

Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases. Melanoma Res (2015) 0.77

Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies. J Pharm Sci (2009) 0.77